Issue 29

For Better or For Worse: Enter the Psychedelics Celebrity

This week, MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced a partnership with self-help guru Deepak Chopra’s The Chopra Foundation, the first high-profile, celebrity-backed deal of its kind for a publicly traded psychedelics company.

While some investors weighed in on social media following the announcement praising the partnership as a boon to MindMed’s profile, others opined the affiliation will damage MindMed’s scientific and academic credibility in the eyes of institutional investors.

The discussion begs the question: will celebrity endorsement become commonplace in psychedelics brand strategy, and how will high-powered affiliation impact investments?

Read More

Register for the PSYCH Investor Summit: Research & Development

Are you keeping up to date on the latest advancements in psychedelic science? Then join us on 7 July for the PSYCH Investor Summit: Research & Development, the must-attend virtual global event for investors and funds eyeing the most promising opportunities in psychedelics today.

Learn how research is paving the way for industry growth; discover the likely timeline for drug trials and commercialisation; and meet one-on-one with the groups and researchers leading the charge.



Pre-clinical programmes aim to uncover if psilocybin can improve eating habits and improve weight loss in obese subjects.

Read More


Recent approval grants the company the authority to proceed with a Phase 2 clinical trial, set to begin in Q3 2021.

Read More


Psychedelic drugs could follow cannabis’ path to legalisation.

MindMed makes further progress on programme to treat anxiety with LSD.

Awakn Life Sciences enters into binding agreement for reverse takeover transaction.

Braxia Health becomes first ketamine therapy provider in Quebec.

Halucenex becomes one of the largest holders of synthetic psilocybin in Canada.

MindMed announces US$160 million 2021 Q1 cash balance.

Psychedelic biotech secures US$125 million investment for programme to treat depression.

MindMed bolsters management team with appointment of vice president of pharmaceutical development.

Toronto-based cannabis company chasing permission to open psilocybin research facility.

ATMA secures supply contract with Havn Life Sciences for naturally derived psilocybin.

IntelGenx reports 2021 Q1 financial results.

Hallucinogens are a US$29 billion ‘new biotech’ sector with massive investment opportunities.

Algernon Pharmaceuticals receives positive feedback from FDA for psychedelic stroke treatment.

Entheon Biomedical launches psychedelics DNA test and announces clinical DMT trial.

Cybin granted approval for clinical trial of psilocybin formula to treat depression.

Psychedelics could be the hottest investment sector of 2021.

Psychedelics as Medicine Report: Second Edition

When it comes to psychedelics, global attitudes are shifting dramatically. In the Psychedelics as Medicine Report: Second Edition, PSYCH conducted a national representative survey to gauge awareness of and attitudes towards the potential use of psychedelics for the treatment of a variety of mental health conditions.

Roughly 45% of respondents reported knowing someone who they believed would benefit from psychedelic therapy and the majority agree more research needs to be done to understand the benefits/effects. This suggests more education is required to inform the wider public about psychedelics and to promote their use as valid, safe and effective alternatives to conventional medications.

Learn more about our approach and how attitudes are shifting in the report.



Psychedelic mushrooms are helping US veterans cope with PTSD.

Imperial College London’s strong case for the approval of class A drugs for depression.

Pharmaceutical psychedelics: what’s already legal and available.

MDMA could help trauma survivors face painful memories.

Inside the psychedelic drug trial that could help cure depression.

Imperial College London on the future of psychedelic science.

The rise of psychedelic therapy in Texas.

Psilocybin-assisted therapy is a new paradigm for mental health.

Survey finds nearly half of US depression sufferers would consider psychedelic treatment.

FDA gives approval for clinical trial where trained therapists will take psychedelics.

Psychedelics may offer PTSD sufferers a new type of treatment.

Use of psychedelics improves colour vision in some colour-blind people.

Everything you need to know about storing LSD.

New study suggests benefits of LSD microdosing may be influenced by placebo effect.

Researchers closer to understanding how psilocybin impacts the brain.


Guide to the evolving legal and regulatory landscape of psychedelics in Canada.

Indigenous groups object to proposed peyote decriminalisation.

California Legislature considering decriminalisation of psychedelic drugs.